In a 55-year-old man with hypertension and rheumatoid arthritis treated with methotrexate and hydroxychloroquine, a 25‑pack‑year smoking history (quit 10 years ago), mild overweight, who now has exertional dyspnea with oxygen saturation dropping to 92 % on walking and basal crackles, could this be pulmonary fibrosis and what diagnostic tests should be ordered?

Yes, this is highly suspicious for rheumatoid arthritis-associated interstitial lung disease (RA-ILD), and you should order high-resolution CT chest and pulmonary function tests immediately.

Clinical Reasoning

This patient has multiple red flags for RA-ILD:

• Exertional dyspnea with oxygen desaturation (92% on ambulation)
• Bibasilar crackles on examination
• Age 55 years (increased risk with age ≥62, but still relevant) 1
• Smoking history (25 pack-years) - a major risk factor 1
• Established RA on disease-modifying therapy

The clinical presentation is classic: progressive dyspnea limiting previously tolerated activity, exertional hypoxemia, and inspiratory crackles. While methotrexate can cause acute hypersensitivity pneumonitis, methotrexate is NOT associated with chronic interstitial lung disease or pulmonary fibrosis 2. The concern here is RA-ILD itself, not drug toxicity.

Diagnostic Testing Algorithm

First-line screening (order both):

1. High-resolution CT (HRCT) chest - This is the most sensitive test with 95.7% sensitivity for detecting ILD 3. Request:

   • Thin-slice reconstruction (<1.5 mm)
   • Inspiratory prone images (to differentiate atelectasis from early fibrosis)
   • Supine end-expiratory imaging (to assess air-trapping)
   • No contrast needed - can be low-dose protocol 3

2. Pulmonary function tests (PFTs) including:

   • Spirometry
   • Lung volumes
   • DLCO (diffusion capacity) - critical as decreased DLCO is associated with RA-ILD 1
   • Ambulatory desaturation testing (6-minute walk with oximetry) 3

The 2023 ACR/CHEST guidelines specifically recommend HRCT chest over PFTs alone for screening patients with systemic autoimmune rheumatic diseases at increased risk of ILD 3. Your patient clearly meets high-risk criteria.

Important Caveats

Methotrexate considerations:

• While the FDA label warns about pulmonary toxicity 4, this typically presents as acute hypersensitivity pneumonitis (fever, dry cough, acute onset) - usually within the first year 5
• Your patient's gradual, progressive symptoms over time are more consistent with RA-ILD than methotrexate toxicity
• Research shows methotrexate is NOT associated with chronic ILD development 2
• Do NOT stop methotrexate yet - wait for diagnostic confirmation, as RA disease activity itself is a risk factor for ILD 1

Hydroxychloroquine note:

• Generally well-tolerated pulmonary-wise
• Main concern is in patients with heart failure (which your patient doesn't appear to have) 6

What NOT to Order

• Chest X-ray alone - inadequate sensitivity; guidelines conditionally recommend AGAINST using chest radiography for monitoring 3
• 6-minute walk distance alone - guidelines recommend against this for monitoring 3
• Bronchoscopy - not indicated at this stage 3

Next Steps After Testing

If HRCT confirms ILD:

• Assess extent and pattern (usual interstitial pneumonia vs nonspecific interstitial pneumonia)
• Consider rheumatology and pulmonology co-management
• Monitor with PFTs every 3-12 months and ambulatory desaturation testing every 3-12 months 3
• Evaluate RA disease activity - higher activity is independently associated with RA-ILD (OR 3.03) 1

The key pitfall to avoid: Attributing this to methotrexate toxicity and stopping it prematurely. The evidence strongly suggests this is RA-ILD, which requires different management than drug-induced pneumonitis.